Life-extending prostate cancer drug to be offered to thousands in England
Abiraterone will be made available on the NHS in England to high-risk non-metastatic prostate cancer patients, potentially saving hundreds of lives annually.
New AI test can predict which men will benefit from prostate cancer drug
An AI tool predicts which prostate cancer patients will benefit from abiraterone, allowing for more tailored treatment and reducing unnecessary procedures.
